Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Patients With HER2+ Metastatic Breast Cancer Experience Consistent PFS Benefit With Trastuzumab Deruxtecan

Patients With HER2+ Metastatic Breast Cancer Experience Consistent PFS Benefit With Trastuzumab Deruxtecan

January 14th 2022, 7:00pm

An expert discusses the implications of a subgroup analysis of the DESTINY-BREAST03 trial, which highlighted the efficacy of trastuzumab deruxtecan in HER2-positive metastatic breast cancer.

Datopotamab Deruxtecan Demonstrates Manageable Safety Profile in TNBC

Datopotamab Deruxtecan Demonstrates Manageable Safety Profile in TNBC

January 10th 2022, 7:00pm

Compared with other antibody-drug conjugates, datopotamab deruxtecan was associated with lower rates of neutropenia, pneumonitis, and hematologic toxicity.

Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet Regimen

Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet Regimen

January 9th 2022, 4:00pm

A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.

Oral Elacestrant Requires Patient Education in Metastatic ER+ Breast Cancer

Oral Elacestrant Requires Patient Education in Metastatic ER+ Breast Cancer

January 5th 2022, 3:00pm

Nausea and upper GI discomfort are frequently linked with use of the oral SERD.

Nursing Considerations for Using Selinexor in Multiple Myeloma

Nursing Considerations for Using Selinexor in Multiple Myeloma

January 3rd 2022, 7:00pm

An expert from the Tisch Cancer Institute highlights the importance of medication adherence, nausea management, and proper hydration for patients being treated with selinexor for relapsed or refractory multiple myeloma.

Genomic Alterations in Primary Breast Cancer May Increase Risk of Secondary Uterine Cancer in Patients Receiving Tamoxifen

Genomic Alterations in Primary Breast Cancer May Increase Risk of Secondary Uterine Cancer in Patients Receiving Tamoxifen

December 31st 2021, 7:00pm

PI3K-pathway mutations may predict an increased risk of secondary uterine cancer in patients receiving tamoxifen to treat primary breast cancer.

Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL

Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL

December 29th 2021, 7:00pm

A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.

 Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast Cancer

Forgoing Select Lymph Node Dissection Linked With Superior Outcomes in Early-Stage Breast Cancer

December 28th 2021, 7:00pm

Updates from the ongoing INSEMA trial suggest that patients with early-stage breast cancer maintain superior quality of life by forgoing sentinel lymph node biopsy and axillary lymph node dissection.

Monitoring Amphiregulin May Be Warranted in Caring for Patients with Acute GVHD

Monitoring Amphiregulin May Be Warranted in Caring for Patients with Acute GVHD

December 19th 2021, 4:00pm

Patients with high levels of amphiregulin were at a higher risk of an early death in acute graft-versus-host-disease, according to a presentation at the 2021 ASH Annual Meeting.

Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Appears Safe in Relapsed/Refractory Multiple Myeloma

Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Appears Safe in Relapsed/Refractory Multiple Myeloma

December 18th 2021, 4:00pm

Belantamab mafodotin is an antibody-drug conjugate that functions by targeting BCMA and has demonstrated clinically meaningful activity in relapsed/refractory multiple myeloma.